Research programme: neurological disorder therapies - Ipsen

Drug Profile

Research programme: neurological disorder therapies - Ipsen

Alternative Names: recombinant botulinum toxins - Ipsen

Latest Information Update: 15 Oct 2016

Price : $50

At a glance

  • Originator Ipsen
  • Developer Harvard University; Ipsen
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Recombinant proteins
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours; Neurological disorders; Neuromuscular disorders

Most Recent Events

  • 14 Oct 2016 Preclinical trials in Neuromuscular disorders, Neurological disorders and Neuroendocrine tumours in France (unspecified route) (Ipsen pipeline, October 2016)
  • 01 Apr 2015 Ipsen and Harvard University expand their collaboration for the development of therapeutics for Neuroendocrine tumours and Neuromuscular disorders
  • 01 Apr 2015 Early research in Neuroendocrine tumours and Neuromuscular disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top